(EXENS) EXOSENS PROM - Ratings and Ratios
Image Intensifiers, Infrared Cameras, Detection Systems, X-Ray Components, Microwave Devices
Dividends
| Dividend Yield | 0.22% |
| Yield on Cost 5y | 0.45% |
| Yield CAGR 5y | % |
| Payout Consistency | 100.0% |
| Payout Ratio | 8.1% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 46.2% |
| Value at Risk 5%th | 71.2% |
| Relative Tail Risk | -6.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.01 |
| Alpha | 140.64 |
| CAGR/Max DD | 2.31 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.385 |
| Beta | 0.045 |
| Beta Downside | 0.145 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.04% |
| Mean DD | 8.49% |
| Median DD | 7.94% |
Description: EXENS EXOSENS PROM November 10, 2025
Exosens Prom (ticker EXENS) is a French-based developer, manufacturer, and global seller of electro-optical technologies, operating across Europe, North America, Asia, Oceania, Africa, and other international markets. Founded in 1937 and headquartered in Mérignac, the firm leverages legacy brands-including Photonis, Xenics, Telops, and El-Mul-to serve a diversified clientele.
The product portfolio spans image-intensifier tubes, UV/IR (short-wave, long-wave, mid-wave) and visible-near-IR cameras, enhanced-vision equipment, ion/electron and scintillation detectors, single-photon detection units, X-ray components, neutronic imaging solutions, gamma and neutron detectors, mineral-insulated extensions, power tubes, microwave devices, and airborne methane detection systems. Its end-markets cover defense and surveillance, industrial research and process control, life-science and environmental monitoring, as well as nuclear applications.
Key industry drivers include a projected ~7 % CAGR for the global electro-optical market through 2030, rising defense budgets in Europe (EU-wide defense spending grew ~4 % YoY in 2023), and increasing demand for advanced sensing in clean-energy and nuclear safety sectors. Assuming EXENS maintains its historical R&D intensity (~12 % of revenue) and leverages the strong brand equity of Photonis in image intensifiers, the company could capture incremental market share as supply-chain constraints ease. For a deeper quantitative assessment, you may find the ValueRay platform’s analyst notes on EXENS useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (58.6m TTM) > 0 and > 6% of Revenue (6% = 42.3m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 5.33pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 26.80% (prev 24.72%; Δ 2.08pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.15 (>3.0%) and CFO 130.5m > Net Income 58.6m (YES >=105%, WARN >=100%) |
| Net Debt (178.7m) to EBITDA (144.6m) ratio: 1.24 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (50.8m) change vs 12m ago 67.12% (target <= -2.0% for YES) |
| Gross Margin 43.14% (prev 44.54%; Δ -1.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 92.57% (prev 50.92%; Δ 41.65pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.31 (EBITDA TTM 144.6m / Interest Expense TTM 34.7m) >= 6 (WARN >= 3) |
Altman Z'' 2.95
| (A) 0.22 = (Total Current Assets 313.8m - Total Current Liabilities 124.8m) / Total Assets 867.3m |
| (B) 0.09 = Retained Earnings (Balance) 79.7m / Total Assets 867.3m |
| (C) 0.15 = EBIT TTM 114.9m / Avg Total Assets 761.9m |
| (D) 0.20 = Book Value of Equity 87.0m / Total Liabilities 437.8m |
| Total Rating: 2.95 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.94
| 1. Piotroski 6.50pt |
| 2. FCF Yield 3.57% |
| 3. FCF Margin 11.47% |
| 4. Debt/Equity 0.63 |
| 5. Debt/Ebitda 1.24 |
| 6. ROIC - WACC (= 18.90)% |
| 7. RoE 14.60% |
| 8. Rev. Trend 77.57% |
| 9. EPS Trend 70.71% |
What is the price of EXENS shares?
Over the past week, the price has changed by +7.27%, over one month by -2.49%, over three months by +22.78% and over the past year by +148.54%.
Is EXENS a buy, sell or hold?
What are the forecasts/targets for the EXENS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.7 | 10.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 54.5 | 21.1% |
EXENS Fundamental Data Overview November 27, 2025
Market Cap EUR = 2.09b (2.09b EUR * 1.0 EUR.EUR)
P/E Trailing = 33.374
P/E Forward = 21.2766
P/S = 4.8416
P/B = 4.896
Beta = None
Revenue TTM = 705.3m EUR
EBIT TTM = 114.9m EUR
EBITDA TTM = 144.6m EUR
Long Term Debt = 247.5m EUR (from longTermDebt, last quarter)
Short Term Debt = 5.09m EUR (from shortTermDebt, last quarter)
Debt = 268.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 178.7m EUR (from netDebt column, last quarter)
Enterprise Value = 2.27b EUR (2.09b + Debt 268.4m - CCE 89.8m)
Interest Coverage Ratio = 3.31 (Ebit TTM 114.9m / Interest Expense TTM 34.7m)
FCF Yield = 3.57% (FCF TTM 80.9m / Enterprise Value 2.27b)
FCF Margin = 11.47% (FCF TTM 80.9m / Revenue TTM 705.3m)
Net Margin = 8.31% (Net Income TTM 58.6m / Revenue TTM 705.3m)
Gross Margin = 43.14% ((Revenue TTM 705.3m - Cost of Revenue TTM 401.1m) / Revenue TTM)
Gross Margin QoQ = 61.96% (prev 22.70%)
Tobins Q-Ratio = 2.62 (Enterprise Value 2.27b / Total Assets 867.3m)
Interest Expense / Debt = 2.55% (Interest Expense 6.84m / Debt 268.4m)
Taxrate = 27.30% (10.5m / 38.4m)
NOPAT = 83.5m (EBIT 114.9m * (1 - 27.30%))
Current Ratio = 2.51 (Total Current Assets 313.8m / Total Current Liabilities 124.8m)
Debt / Equity = 0.63 (Debt 268.4m / totalStockholderEquity, last quarter 429.5m)
Debt / EBITDA = 1.24 (Net Debt 178.7m / EBITDA 144.6m)
Debt / FCF = 2.21 (Net Debt 178.7m / FCF TTM 80.9m)
Total Stockholder Equity = 401.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.76% (Net Income 58.6m / Total Assets 867.3m)
RoE = 14.60% (Net Income TTM 58.6m / Total Stockholder Equity 401.5m)
RoCE = 17.70% (EBIT 114.9m / Capital Employed (Equity 401.5m + L.T.Debt 247.5m))
RoIC = 24.59% (NOPAT 83.5m / Invested Capital 339.7m)
WACC = 5.69% (E(2.09b)/V(2.36b) * Re(6.18%) + D(268.4m)/V(2.36b) * Rd(2.55%) * (1-Tc(0.27)))
Discount Rate = 6.18% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 29.27%
[DCF Debug] Terminal Value 74.73% ; FCFE base≈59.1m ; Y1≈47.7m ; Y5≈32.9m
Fair Price DCF = 11.99 (DCF Value 610.3m / Shares Outstanding 50.9m; 5y FCF grow -23.14% → 3.0% )
EPS Correlation: 70.71 | EPS CAGR: 1000.0% | SUE: 4.0 | # QB: 1
Revenue Correlation: 77.57 | Revenue CAGR: 55.11% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.77 | Chg30d=+0.012 | Revisions Net=+3 | Growth EPS=+24.7% | Growth Revenue=+14.5%